John Ansell, MBA
Director, John Ansell Consultancy
Member of the Healthcare Council
Council Member Biography
John Ansell, MBA, has been the Director of John Ansell Consultancy, a pharmaceutical consulting firm in Thame, United Kingdom, since November 1990. Mr. Ansell has advised some 120 pharma, biotech and companies providing pharmaceutical services. He focuses on international marketing and business development projects, reflecting his 20 years experience in the pharma industry with Organon, Schering AG, Fisons, Solvay and Glaxo. Mr. Ansell has acted as Chairman at over 30 pharma conferences, is a frequent speaker on marketing, deals and R&D strategy, and has authored over 40 articles. Mr. Ansell's qualifications are in Biochemistry (BSc Hons, Liverpool University) and Business Studies (MA, Sheffield University). He is Honorary Consultant to Manchester University Pharmacy School. Mr. Ansell is the author of a new Falconbury distance learning course "Understanding the Pharmaceutical Industry". He was appointed Chairman of the Advisory Board of Decision Resources in 2005. (This is me - Update Profile)
Employment History
- 1990 - present
- Director, John Ansell Consultancy
GLG NewsSM Analyses by John Ansell, MBA(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
A triple combination for H1N1: good in principle
October 30, 2009
John Ansell, MBA, Director, John Ansell Consultancy
Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1 | www.medicalnewstoday.com
The principle behind Adamas’s triple combination development for influenza is a good one. There is clearly a need for improved treatments, as the latest wave of swine flu is now showing. Oseltamivir (Tamiflu) and ribavirin are reasonable drugs to select but the third component, amantadine, may prove...
-
GSK's new venture into Duchenne's makes sense
October 14, 2009
John Ansell, MBA, Director, John Ansell Consultancy
GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy | www.pipelinereview.com
GSK's latest deal on Duchenne's muscular dystrophy with the Dutch company Prosena is a further indication of the former's interest in diversifying out of the more obvious, major areas of medicine.This can make sense: such "esoteric" indications areas are less well understood, there is less competition...
-
What does Solvay offer to a bidder ?
September 25, 2009
John Ansell, MBA, Director, John Ansell Consultancy
Sources: Abbott sparks Solvay bidding war, UCB may follow | www.fiercebiotech.com
In considering the outcome of the current bidding war, what can Solvay Pharmaceuticals offer to an acquirer ? It can’t be the R & D pipeline. In 2004 Solvay was described by one industry observer as having a great pipeline. But except for one modest short-term success in the market, all of the projects...
-
Dainippon Sumitomo acquires a bridgehead and settles Sepracor's uncertain future
September 4, 2009
John Ansell, MBA, Director, John Ansell Consultancy
Dainippon Sumitomo Pharma to Acquire Sepracor for U.S. $23.00 Per Share in an All-Cash Tender Offer Valued at Approximately U.S. $2.6 Billion | www.pipelinereview.com
In acquiring Sepracor, Dainippon Sumitomo is gaining a modest-sized commercial bridgehead for marketing its products in North America, but one which by itself had an uncertain future. Dainippon Sumitomo will need to take action to stabilize a company which has been facing issues concerning its future...
Leading institutions connect with John Ansell, MBA through GLG
GLG Study Groups with John Ansell, MBA(?)
| Study Group Name | No. Members |
|---|---|
| Generic Drug Economic Experts | 766 |
| Generic Pharmaceuticals Economic Experts (Germany) | 48 |
GLG Live Meetings with John Ansell, MBA(?)
John Ansell, MBA has not participated in any GLG Live Meetings.